Potential Acquisition

London, 26 January 2021 - The Board of Hikma Pharmaceuticals Plc (Hikma) notes the disclosure made today to the Egyptian Exchange by GlaxoSmithKline S.A.E. (GSK SAE), the listed Egyptian subsidiary within the GlaxoSmithKline plc group of companies (GSK). Hikma confirms that it has entered into a non-binding term sheet with GSK for the purposes of potentially acquiring GSK’s interests in certain entities that conduct, and certain assets comprising, GSK’s pharmaceutical and consumer commercialisation and manufacturing business in Egypt and GSK’s pharmaceutical business in Tunisia (the Proposed Transaction).

Press Release Corporate 26 January 2021

text 1

In addition and subject to receipt of GSK SAE’s board consent, Hikma hereby announces that it expects to conduct a due diligence exercise, the results of which will form the basis for further discussions with GSK in connection with the Proposed Transaction.

The Proposed Transaction is subject to a number of conditions, including the finalisation of definitive and legally binding documents and the completion of due diligence by Hikma. As such, there can be no guarantee at this stage that the Proposed Transaction will progress.

Hikma will provide further updates in due course.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.